PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.91%
Revenue growth at 50-75% of MRVL's 22.86%. Martin Whitman would worry about competitiveness or product relevance.
-17.38%
Negative gross profit growth while MRVL is at 33.65%. Joel Greenblatt would examine cost competitiveness or demand decline.
52.33%
EBIT growth below 50% of MRVL's 161.81%. Michael Burry would suspect deeper competitive or cost structure issues.
52.33%
Operating income growth under 50% of MRVL's 161.81%. Michael Burry would be concerned about deeper cost or sales issues.
47.70%
Net income growth under 50% of MRVL's 152.48%. Michael Burry would suspect the firm is falling well behind a key competitor.
48.39%
EPS growth under 50% of MRVL's 150.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
48.39%
Diluted EPS growth under 50% of MRVL's 150.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.80%
Share count expansion well above MRVL's 0.36%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.80%
Diluted share reduction more than 1.5x MRVL's 4.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-4.93%
Negative OCF growth while MRVL is at 26.16%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-3.21%
Negative FCF growth while MRVL is at 33.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
509.80%
10Y revenue/share CAGR at 75-90% of MRVL's 604.34%. Bill Ackman would press for new markets or product lines to narrow the gap.
55.35%
5Y revenue/share CAGR at 50-75% of MRVL's 85.87%. Martin Whitman would worry about a lagging mid-term growth trajectory.
8.55%
3Y revenue/share CAGR above 1.5x MRVL's 5.36%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
2607.97%
10Y OCF/share CAGR 1.25-1.5x MRVL's 2360.00%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
526.71%
5Y OCF/share CAGR above 1.5x MRVL's 195.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
663.79%
3Y OCF/share CAGR above 1.5x MRVL's 2.26%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1062.70%
Negative 10Y net income/share CAGR while MRVL is at 3216.06%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1976.89%
Negative 5Y net income/share CAGR while MRVL is 76.18%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-216.66%
Negative 3Y CAGR while MRVL is 23.04%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1568.61%
10Y equity/share CAGR above 1.5x MRVL's 911.39%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
87.24%
5Y equity/share CAGR above 1.5x MRVL's 44.60%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
30.55%
3Y equity/share CAGR above 1.5x MRVL's 11.68%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.63%
AR growth well above MRVL's 15.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
-14.68%
Inventory is declining while MRVL stands at 3.83%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.77%
Asset growth at 75-90% of MRVL's 4.51%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
-3.85%
We have a declining book value while MRVL shows 2.61%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.15%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.10%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-37.77%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.